Alx Oncology Holdings Inc (ALXO) · Oct 15, 2026 · Share issuance
13.35M-share exchange — 13.35M shares exchanged for pre-funded warrants exercisable at $0.001
ALX Oncology’s share exchange retires 13.4 million common shares and replaces them with pre-funded warrants—reshaping ownership, not funding trials.
ALX Oncology is a clinical-stage biotech advancing evorpacept and ALX2004 toward upcoming clinical milestones, with $153.4 million in cash, cash equivalents and investments as of June 30, 2026, and planned funding through the first half of 2028. This filing does not change that operating runway or advance either program.
The company is converting a large block of common stock into pre-funded warrants. Holders will surrender 13,353,384 shares and receive warrants for the same number of shares, with a $0.001 exercise price and cashless exercise available. 〔0〕
The immediate share count falls, but the underlying dilution is largely deferred rather than removed. ALX had 138,276,997 shares outstanding as of July 30, 2026; the exchanged block equals roughly 9.7% of that base. If the warrants are exercised, those shares can return, so this is primarily cap-table and ownership-limit management rather than a permanent reduction in fully diluted exposure.
The transaction appears designed to give major holders more flexibility without forcing them above ownership limits. The warrants impose 4.99% or 9.99% beneficial-ownership caps, with increases allowed up to 19.99% after a 61-day notice period. That suggests the practical objective is managing investor ownership mechanics, not raising money—a filing-based inference rather than an explicit company explanation.
There is no financing benefit here. The shares are surrendered for no consideration, and the $0.001 exercise price is nominal; the filing provides no proceeds, new partnership, clinical result or change to guidance. 〔1〕
Bottom line: This is a meaningful cap-table reshuffle involving nearly 10% of the recent share base, but it does not materially change ALX’s funding, clinical execution or business trajectory. The economic signal is neutral: ownership flexibility changes, while the underlying equity exposure mostly remains available through warrants.
Exchange settlement, October 15, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!